The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 3,604.7 Mn in 2022 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview
Primary sclerosing cholangitis (PSC) is a chronic, progressive liver disease characterized by scarring and inflammation of bile ducts inside and outside of the liver. As bile ducts become blocked ... Read more

Primary Sclerosing Cholangitis (PSC) is a chronic and progressive cholestatic liver disease characterized by inflammation and fibrosis of the bile ducts that can ultimately lead to cirrhosis and death from complications of end-stage liver disease. PSC can occur alone or may be associated with inflammatory bowel disease, mainly ulcerative colitis. The main product types associated with PSC are magnetic resonance cholangiopancreatography, endoscopic retrograde cholangiopancreatography, ... Read more

The primary sclerosing cholangitis (PSC) market is characterized by inflammatory and fibrotic strictures of the bile ducts leading to cholestasis. PSC is a progressive disorder of unknown etiology. The signs and symptoms of PSC include jaundice, fatigue, pruritus, abdominal pain and fever. Currently, ursodeoxycholic acid is the only approved therapy for PSC but it only provides relief from symptoms, rather than slowing disease progression. There is no cure for PSC and patients usually ... Read more